Pharmaceutical Pricing and Medical Innovation
Other featured articles
An Economist’s Change of Heart: It’s Time to Regulate the Prescription- Drug Middlemen
Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients, writes Geoffrey Joyce in Market Watch.
Medicare’s ‘Catastrophic Insurance’ Can Be a Catastrophe for Middle-Income Seniors
Even with Medicare's catastrophic insurance, middle-income seniors can be on the hook for thousands of dollars for their medications each year, write Erin Trish and Geoffrey Joyce in STAT.
Who Wins When a Prescription Copay Exceeds the Drug Price? (Not the Patient)
An interactive graphic shows how frequently the co-payment exceeds the price of commonly prescribed drugs, and provides the average overpayment per drug.
Cultivating a Vibrant U.S. Market for Biosimilars: a Conversation with FDA’s Scott Gottlieb
Biosimilars have been a major focus of the FDA’s efforts to increase competition and choice for patients and the U.S. healthcare system.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.